Crisaborole vs. Tacrolimus for children with eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests whether crisaborole ointment works as well as tacrolimus ointment for children ages 2 to 18 with mild to moderate atopic dermatitis (eczema). If your child has eczema covering less than 30% of their body and hasn't used certain creams or medications recently, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 2 and 18 years old.
- Your child has mild to moderate eczema (atopic dermatitis).
- Eczema covers less than 30% of your child's body.
- No active skin infections (like bacteria, virus, or fungus) in the area to be treated.
- Your child has not used strong steroid creams, certain immune-suppressing ointments, or crisaborole in the last 2 weeks.
- Your child is not allergic to either study medication or its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two prescription creams (tacrolimus and crisaborole) to see which works better and is safer for treating mild to moderate eczema in children and young adults aged 2–20. Both are non-steroid options that may help reduce itching and skin inflammation.
This trial tests if crisaborole ointment works better and is safer than tacrolimus ointment for mild to moderate atopic dermatitis (eczema). It may help you find a new treatment option.
This trial tests if a cream called crisaborole works better than a placebo cream for treating mild to moderate eczema. You'll apply the cream at home twice a day for four weeks, and researchers will see if it helps your skin heal.
This study tests a probiotic ointment for children aged 6 months to 15 years with mild-to-moderate eczema (measured by a skin score of 15–50). It aims to see if the cream is safe and helps improve their skin.
This study tests an investigational shot (tralokinumab) plus a steroid cream for children with moderate-to-severe eczema that hasn't been controlled by creams alone. It aims to see if the combination is safe and works better than the cream alone.
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.